Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: A multicentre prospective cohort study

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 5, 2014, Pages 1552-1557

  Rigatto, Maria Helena ^a   Behle, Tainá F ^b   Falci, Diego R ^c   Freitas, Thiela ^c   Lopes, Natane T ^d   Nunes, Mariá ^d   Costa, Leonardo W ^d   Zavascki, Alexandre P ^b,d  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c HOSPITAL NOSSA SENHORA DA CONCEIÇÃO   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Colistin; Nephrotoxicity; PMB

Indexed keywords

POLYMYXIN B; VASOACTIVE AGENT; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLOODSTREAM INFECTION; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DOSE INCREASE; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; ACUTE KIDNEY INJURY; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; SURVIVAL; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMYXIN B; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84929746737     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku561     Document Type: Article

References (25)

1. Paul M, Carmeli Y, Durante-Mangoni E et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2014; 69: 2305-9.
2. Zavascki AP, Bulitta JB, Landersdorfer CB. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 2013; 11: 1333-53.
3. Landman D, Georgescu C, Martin DA et al. Polymyxins revisited. Clin Microbiol Rev 2008; 21: 449-65.
4. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
5. Yahav D, Farbman L, Leibovici L et al. Colistin: new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18: 18-29.
6. Zavascki AP, Goldani LZ, Li J et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007; 60: 1206-15.
7. Pogue JM, Lee J, Marchaim D et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53: 879-84.
8. Kubin CJ, Ellman TM, Phadke V et al. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. J Infect 2012; 65: 80-7.
9. Akajagbor DS, Wilson SL, Shere-Wolfe KD et al. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 2013; 57: 1300-3.
10. Tuon FF, Rigatto MH, Lopes CK et al. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014; 43: 349-52.
11. Phe K, Lee Y, McDaneld PM et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 2014; 58: 2740-6.
12. Hartzell JD, Neff R, Ake J et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48: 1724-8.
13. Deryke CA, Crawford AJ, Uddin N et al. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54: 4503-5.
14. Gauthier TP, Wolowich WR, Reddy A et al. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56: 2392-6.
15. Kwon JA, Lee JE, Huh W et al. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35: 473-7.
16. Vicari G, Bauer SR, Neuner EA et al. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant Gramnegative bacteremia. Clin Infect Dis 2013; 56: 398-404.
17. Elias LS, Konzen D, Krebs JM et al. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 2010; 65: 2231-7.
18. Abdelraouf K, Braggs KH, Yin T et al. Characterization of polymyxin B-induced nephrotoxicity: implications for dosing regimen design. Antimicrob Agents Chemother 2012; 56: 4625-9.
19. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31.
20. Chawla LS, Eggers PW, Star RA et al. Acute kidney injury and chronic kidney disease as interconnected syndromes. New Engl J Med 2014; 371: 58-66.
21. Bellomo R, Ronco C, Kellum JA et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
22. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
23. Abdelraouf K, He J, Ledesma KR et al. Pharmacokinetics and renal disposition of polymyxin B in an animal model. Antimicrob Agents Chemother 2012; 56: 5724-7.
24. Abdelraouf K, Chang KT, Yin T et al. Uptake of polymyxin B into renal cells. Antimicrob Agents Chemother 2014; 58: 4200-2.
25. Balkan II, Dogan M, Durdu B et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis 2014; 46: 678-85.